• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Charles River Partners with JADE
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Flow Sciences

    Cytovance Biologics

    Syngene

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Adare Pharma Solutions

    Baxter BioPharma Solutions

    PCI Pharma Services

    Flow Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biopharma Manufacturing Markets

    Biomanufacturing contract services and supplies markets continue to expand

    Biopharma Manufacturing Markets
    Biopharma Manufacturing Markets
    Table 1: Worldwide Capacity and Facilities Summary Data
    Biopharma Manufacturing Markets
    Table 2: Regional Bioprocessing Concentration, based on Facility Index Ranking
    Biopharma Manufacturing Markets
    Table 3: Some Biopharmaceuticals Manufacturing-related Market Estimates, 2018 and 2023
    Related CONTENT
    • Asymchem
    • Vetio Animal Health
    • Biosimilar Market Trends
    • CDMOs and Drug Shortages
    • Biopharmaceuticals Outsourcing Slows
    Ronald A. Rader and Eric S. Langer, BioPlan Associates05.08.18
    Biopharmaceutical products continue to expand globally, spurring growth in related bioprocessing supplies and services, which are tracking along with this worldwide growth. Over the past 20 years, the broader pharmaceutical industry has integrated biopharmaceuticals into its portfolio of therapeutics. In fact, many leading pharma companies are now dependent on these products for their pipeline and revenue. An estimated 40% of all pharmaceutical R&D expenditures and products in the pipeline, likely up to 5,000, are biopharmaceuticals. A significant portion of this development pipeline, ≥1,500 products, is follow-on biopharmaceuticals, mostly biosimilars but many biogenerics and biobetters.2 Follow-on product development mostly involves adopting current vs. legacy bioprocessing technologies, with cost-effective manufacturing needed for these products to be competitive.3

    A large portion of the biopharmaceuticals coming to market involve therapeutics for smaller markets, or currently untreatable indications, making them particularly needed. With their cost of manufacture generally much higher, biopharmaceuticals (vs. drugs) tend to be developed for indications generally lacking current good options for treatment, assuring them of markets upon launch along with willingness to pay higher prices. In recent years, this has included a growing number of products for orphan indications.

    Biopharmaceuticals Market Growth
    Biopharmaceuticals (vs. drugs) have now for decades proven themselves to be profitable, e.g., with higher profits per sale and likelihood of attaining success, including products making it through the development pipeline, gaining approvals, and capturing market share. Total product revenue (sales) for biopharmaceuticals has been growing steadily at ≥12% annually since the initial market launches of recombinant proteins three decades ago; and many biopharmaceutical manufacturing-related benchmarks have much the same growth rates. Current (mid-2018), worldwide biopharmaceutical revenue is at a rate of ~$275 billion/year. The world market for recombinant protein therapeutics is now ~$150 billion; and the world market for all pharmaceuticals in now ~$1.1 trillion. 

    Consistent growth in biopharmaceutical revenue and manufacturing is primarily due to new products entering world markets; and secondarily, expansion of markets for existing products, particularly for new indications. Approvals in 2017 included a record number and the highest proportion of products being recombinant vs. non-recombinant. Note, despite the ups-and-downs with approvals, the related increases in terms of annual biopharmaceutical revenue have generally remained much the same from year-to-year, ≥12%.

    New Product Classes Bringing Growth
    New classes of products are expanding world markets as recombinant and monoclonal antibodies are increasingly becoming ‘legacy products’ that are being targeted for biosimilars and biogenerics development. First-in-their-class approvals of cellular and gene therapy products were granted by FDA in 2017, including two autologous (patient’s own cells cultured) CAR-T cell products incorporating gene therapy modifications and a viral vector gene therapy product. This is just the start of an expected rapid growth in cellular and gene therapies. Product development is intense such that there is currently an estimated 400%-500% shortfall or ‘capacity crunch’ in terms of available manufacturing capacity, particularly among CMOs.6 That is, five times the current cell therapy manufacturing capacity would be used if it were available. And although at present the total capacity required is rather small, there is a projected very large cell/gene therapy capacity shortfall likely to occur within the next five years. As an indication, anecdotal insights from current CMOs indicate an average backlog to start a cellular/gene therapy project at a competent cell therapy CMO is now 18 months. The few leading CMOs in these sectors are building capacity to handle their backlogs of R&D and clinical supplies projects, with none yet building what will be needed to support commercial manufacturing of these products. 

    As a cautionary tale, in the early 1990s, many now Big (Bio)Pharma companies built huge and terribly inefficient manufacturing facilities, e.g., ≥100,000 L monoclonal antibody manufacturing facilities operating at ≤3% of current productivity (titers) using less-than-optimized methods. We similarly expect established companies to focus on the cellular and gene therapies sectors, including supporting expansions of manufacturing worldwide. The cellular/gene therapy sectors, like the early mAb manufacturers, will find it necessary to spend whatever is needed to commercialize and market their products. As a result, suppliers to cellular/gene therapy facilities will see significantly increased sales of bioprocessing supplies relative to conventional bioprocessing, because cellular therapies bioprocessing at present tends to consume more materials. For example, large amounts of single-use equipment are used for manufacture of each single autologous patient’s product or allogeneic (multi-patient) batch/lot, e.g., often up to 200 fluid transfers (connectors, containers, etc.), multiple cycles of cell culturing-washing-separation, etc. 

    Biosimilars and other follow-on biological products are another rapid growth area, with patents expiring on many established biopharmaceuticals. Follow-ons include biosimilars and biobetters in developed countries and biogenerics in developing countries. The Biosimilars/Biobetters Pipeline Directory currently tracks >960 biosimilars/biogenerics in development or marketed.2 Follow-ons are bringing in many new biopharmaceutical players, with many constructing their own facilities, often single-use-based. This includes generic pharmaceutical companies and new entrants based in China, India and other developing countries increasingly entering the biopharmaceutical industry through follow-on products.
    Other factors leading to increases in the number of biopharmaceutical facilities and manufacturing worldwide include:
    • Backup/second-source facilities: Manufacturers of most every commercially successful biopharmaceutical sooner or later, need to have a second manufacturing source for each product, whether a CMO or another company-owned facility. The risks to products and company survival from not being able to meet market demand are too high for any manufacturer to ignore;
    • Developing countries are increasingly demanding foreign biopharmaceutical companies manufacture products domestically or partner with local companies to address domestic markets. Various counties’ governments, e.g., Brazil, are slowly developing their own captive biopharmaceuticals manufacturing facilities and markets. China, in particular is rapidly growing their bioprocessing segment (see below); and
    • A slow-down in large company acquisitions of other large companies is having a positive effect, with companies investing more in developing manufacturing infrastructure vs. in mergers and acquisitions (M&A) to distract investors.
    Productivity Continues to Increase
    A factor contributing to lower costs for bioprocessing, allowing this to be done at smaller scales, while the numbers of products, facilities and process lines increase, resulting in overall market growth, is the slow but steady increase in bioprocessing productivity, particularly upstream bioreactor titers.7 Average titers, e.g., for mAbs manufacturing, have increased from about 0.1 g/L three decades ago to now about 3.8 g/L, with growth in productivity paralleling growth of biopharmaceutical product markets with similar ≥12% average annual increases. Downstream/purification yields have not increased much in recent decades, but purification now includes more options, including membranes replacing chromatography columns and continuous chromatography starting to enter the market.

    The largest growth in biopharmaceutical manufacturing in the past decade has been in single-use systems, disposable bioprocessing supplies. These now totally dominate pre-commercial—R&D and clinical scale—biopharmaceutical manufacturing, accounting for ~85% of this segment of bioprocessing; and developing manufacturing capacity measured as total bioreactor volume is quicker and more adaptable to needs. However, larger-scale commercial manufacturing continues to be dominated by fixed stainless steel-based manufacturing, with this still more cost-effective at large(st) scales. Although there are fewer stainless steel facilities being constructed, with single-use systems starting to be adopted for commercial manufacturing, there continues to be dramatic expansion of stainless steel commercial manufacturing capacity, exemplified by the new super-sized facilities of Samsung and Celltrion in S. Korea, with these facilities having >500 million L total capacity.

    Numerically most new facilities and process lines will increasingly be single-use based. Recurring costs for equipment are much higher with single-use vs. fixed stainless steel, with totally new equipment swapped-in with each new run/batch/lot. So the single-use facilities-related bioprocessing supplies market has expanded more rapidly than that for stainless steel systems. There will be increased single-use facilities at the expense of stainless steel ones in the future as more orphan, biosimilar and other products with smaller markets, less product needed to be manufactured, continue to receive approvals, and as scaling-out with single-use bioreactors is adopted for commercial manufacturing.

    Market Expansion in Asia and Globally
    Biopharmaceutical manufacture outside of the developed major market countries is increasing rapidly. BioPlan’s Top 1000 Global Biopharmaceutical Facilities Index ranks the top 1,000+ facilities worldwide in terms of known or estimated bioprocessing capacity (cumulative onsite bioreactor volume), number of biological products manufactured, and bioprocessing-related employment.8 Over the past eight years, we have identified and tracked global facilities, including recombinant products, vaccines, biosimilars, and veterinary biologics. The database excludes blood and plasma-derived therapeutics, synthetic peptides and diagnostics.

    The database now tracks over ~16.5 million L of active production capacity at over 1,500 facilities worldwide, including 6 million L (37%) in the U.S./Canada, 5.5 million L in Western Europe (33%) and 4.7 million L (25%) in Asia Pacific, including 870 thousand L in China and 941 thousand L in India. These capacity figures are significantly higher than other available capacity data resources, partly because we include active capacity from all global sources, including biogeneric production, veterinary vaccines, and non-GMP capacity that may be used for therapeutics in lesser regulated markets. While such facilities may not currently be selling biologics in regulated western markets, they should be counted as part of global capacity. Further, their needs for bioproduction tools, technologies and services may be as important to their domestic markets as they are in developed markets.  In addition, given the global nature of biopharmaceuticals, many of these facilities may eventually, in the not-too-distant future, be producing API, biosimilars, or finished innovative biologics for global markets.

    Much new manufacturing capacity is being added internationally, with biopharmaceutical markets in many developing countries growing and more domestic companies increasingly serving these markets, generally with biogeneric copies of innovator products. Advances in bringing biopharmaceutical manufacturing capacity online have been particularly notable in China and India.9,10 Major growth in biopharmaceutical CMO capacity is expected in China, with regulations changing to allow third parties (CMOs) to be hired to manufacture clinical and commercial biopharmaceutical products. Otherwise, China is building capacity and adopting newer technology faster than India, and will be pulling ahead of India in terms of demand for biopharmaceutical manufacturing and related services. Much of India’s well established biologics manufacturing expertise and capacity centers on vaccines production, while China’s is seeking to expand in a broad range of platform areas.

    These and other foreign countries bioprocessing capacities are growing at a much more rapid rate than major Western markets, but since most have recently started from near-zero baselines, this growth rate will likely taper off. However, developing countries for the foreseeable future do not pose a threat to U.S. and European dominance of the biopharmaceutical industry, particularly highly profitable innovative product development and manufacturing. Regardless, the demand in developing regions for bioprocessing tools and services will continue to grow.

    Many large companies in China, India and other developing countries are bringing commercial-scale biopharmaceutical manufacturing and CMO facilities online to serve domestic and regional needs, including many targeting eventual full cGMP manufacture to supply Western markets. Markets for bioprocessing supplies and services are increasing in developing countries. Various major bioprocessing suppliers have been reporting double-digit sales growth in Asian markets. There are currently just small but growing amounts of bioprocessing supplies being manufactured in developing countries, notably China, with these currently targeting domestic non-GMP research and biogenerics manufacturing markets. But the companies in China, India, Brazil and elsewhere that are targeting eventual sales in highly-regulated countries are mostly investing in U.S.- and European-sourced GMP-ready bioprocessing supplies.

    Market (Facilities) Distribution
    Biopharmaceutical manufacturing (bioprocessing) facilities compose the great majority of the manufacturing-related supplies and services, with R&D facilities just a small portion. BioPlan estimates from our Top 1000 Bio database and other data resources total worldwide bioprocessing capacity is now ~16.5 million L. Table 1 presents some top-level capacity and facilities data. 


    Table 1. Worldwide Capacity and Facilities Summary Data


    The online Top 1000 Global Biopharmaceutical Facilities Index contains records for over 1,050 facilities, those facilities with ≥500 L capacity, accounting for 99.5% of the total capacity worldwide.8 Facilities with ≥1,000 L capacity are generally involved in commercial products manufacturing, with these facilities having 98.7% of worldwide capacity. An estimated 68% of the ≥15 million L culture/fermentation-based capacity (capacity for blood/plasma products excluded), ~10.2 million L, is mammalian, the great majority for manufacture of monoclonal antibodies, nearly all using CHO host cells. Essentially all the rest, ~5 million L, is microbial, most all of which is using E. coli host cells.

    Regional Concentration of Bioprocessing
    Because capacity is only one measure of a region’s bioprocessing presence, we assess regional capability based on four factors: Capacity, bioprocessing employment, number of commercial biologics at a facility, and number of clinical-scale biologics being produced. We use these data to create a ranking scale for each facility. This “Facility Index” can then be used to define a region’s overall concentration, and these total numbers can be used to more accurately compare and predict where robust capacity and employment is occurring. Regional distribution of facilities and capacity is shown in Table 2.


    Table 2. Regional Bioprocessing Concentration, based on Facility Index Ranking


    The U.S. and Western Europe continue to be the leaders in biopharmaceutical R&D, number of companies, and biopharmaceutical revenue. This is reflected in facilities and capacity data, with Average Capacity/Facility being an indicator of average size of facilities.  North America is the leading region in terms of total manufacturing capacity, very closely followed by Europe and then Asia. Besides having the most capacity, the U.S. has the largest number of development facilities, which reduces its Average Capacity/Facility.

    Supplies and Services Markets
    Based on our analyses over the past 28 years, the market for bioprocessing tools, materials and services continues to grow at between 12 and 14% annually.11 The current worldwide market for biopharmaceutical manufacturing-related goods and services, the direct costs of products manufacturing, is currently ≥ $22.0 billion or ~8.0% of current biopharmaceuticals revenue. This includes bioprocessing supplies and CMO, CRO and other services. This does not include in-house staff or indirect costs, including costs of financing/debt servicing, utilities, real estate, internal storage, managerial overhead, and other infrastructure-type costs.


    Table 3. Some Biopharmaceuticals Manufacturing-related Market Estimates, 2018 and 2023


    Bioprocessing supplies is a healthy, consistently-growing market, with growth generally tracking that of related products’ revenue. Those facilities performing late-stage and, particularly, commercial manufacturing account for about 90% bioprocessing supplies consumption and revenue, e.g., just the Protein A resins used for initial monoclonal antibody purification for a large-scale bioreactor run can cost $millions. This includes the 600+ facilities worldwide each with ≥1,000 L capacity known to be commercially manufacturing products. 

    BioPlan’s annual survey data are showing that biopharmaceutical industry outsourcing is becoming more strategic and long-term.11 Companies, including Big Pharma that formerly eliminated in-house capabilities to cut staffing and outsource feasible operations are now taking a more sophisticated approach. Companies carefully evaluate and weigh their manufacturing options, including assessing options from longer-term perspectives. 

    Conclusions
    Growth in the biopharmaceutical manufacturing-related supplies and services markets continues steadily, closely paralleling growth of biopharmaceutical products revenue, generally in the 12%-15%/year range. These markets are growing about twice the rate of those for non-biopharmaceutical products (primarily small molecule drugs). There is every reason to assume that future growth in biopharmaceutical sales and related manufacturing markets will continue, nearly doubling about every 5-6 years. 

    References
    1. Rader, R.A. “(Re)Defining Biopharmaceutical,” Nature Biotechnology, vol. 26, 743–751, 2008.
    2. Rader, R.A., Biosimilars/Biobetters Pipeline Directory, online database at www.biosimilarspipeline.com).
    3. Rader, R.A., Biosimilars Paving the Way for Cost-Effective Bioprocessing,” Biosimilars Development, https://www.biosimilardevelopment.com/doc/biosimilars-paving-the-way-for-cost-effective-bioprocessing-0001, Aug. 23, 2017.
    4. Rader, R.A., BIOPHARMA:  Biopharmaceutical Products in the U.S. and European Markets:  U.S. Approvals, 2002-present,” list online at http://www.biopharma.com/approvals.html.
    5. Rader, R.A.,  BIOPHARMA:  Biopharmaceutical Products in the U.S. and European Markets, online database at www.biopharma.com.
    6. Rader, R.A., "Cell and Gene Therapies: Industry Faces Potential Capacity Shortages," Genetic Engineering & Biotechnology News (GEN), 37(20), Nov. 15, 2017.
    7. Rader, R.A., Langer, E.S., “Thirty Years of Upstream Bioprocessing Improvements,” BioProcess International, 14(2), Feb. 2015, p. 10-14.
    8. Langer, E.S., Rader, R.A., “Top 1000 Global Biopharmaceutical Facilities Index,” online database at http://top1000bio.com.
    9. Xia, V., Yang, L.C., Langer, E.S., Directory of Top 60 Biopharmaceutical Manufacturers in China, 357 pages, Feb. 2017.
    10. Xia, V., Yang, L.C., Langer, E.S., “Chinese & Indian GMP Biologics Exports - Surveying The Current Landscape,” Bioprocess Online, https://www.bioprocessonline.com/doc/chinese-indian-gmp-biologics-exports-surveying-the-current-landscape-0001, June 2, 2017.
    11. Langer, E.S., et al., Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, 14th edition, BioPlan Associates, April 2017.

    Ronald A. Rader is senior director, technical research at BioPlan Associates. He has more than 25 years of experience as a biotechnology, pharmaceutical and chemical information specialist and publisher.

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports. elanger@bioplanassociates.com; 301-921-5979; www.bioplanassociates.com
    Related Searches
    • CMO
    • asia pacific
    • contractpharma.com
    • marketing
    Suggested For You
    Asymchem Asymchem
    Vetio Animal Health Vetio Animal Health
    Biosimilar  Market Trends Biosimilar Market Trends
    CDMOs and Drug Shortages CDMOs and Drug Shortages
    Biopharmaceuticals Outsourcing Slows Biopharmaceuticals Outsourcing Slows
    FDA Approves Grifols FDA Approves Grifols' Facility for Production of Recombinant Proteins
    Are Indian Generic Firms Improving Compliance? Are Indian Generic Firms Improving Compliance?
    FDA Grants Soleno FTD FDA Grants Soleno FTD
    Rockwell Medical Announces FDA Approval Rockwell Medical Announces FDA Approval
    Samsung BioLogics Selects Veeva Vault QualityDocs Samsung BioLogics Selects Veeva Vault QualityDocs
    18	ALLERGAN 18 ALLERGAN
    FDA Approves GW Pharma FDA Approves GW Pharma's Epidiolex
    Samsung BioLogics Licensed by Health Canada Samsung BioLogics Licensed by Health Canada
    Samsung BioLogics Details End-To-End Services Samsung BioLogics Details End-To-End Services
    Semi-Solid Dosage Forms Semi-Solid Dosage Forms

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Biosimilars
      Biosimilar Manufacturing Strategies

      Biosimilar Manufacturing Strategies

      Five steps to competing in a post-patent expiry era.
      George I’ons, Owen Mumford Pharmaceutical Services 09.09.20


    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20

    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20


    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20

    • Biosimilars
      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      Biosimilar uptake set to reshape the U.S. market
      Katya Svoboda and Bob Swann, ICON 05.05.20

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20


    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20

    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    • Biologics, Proteins, Vaccines
      Biopharma Contract Manufacturing Pricing Analysis

      Biopharma Contract Manufacturing Pricing Analysis

      Expect increased prices over the next two years, but at slightly lower than historical trends
      William Downey, HighTech Business Decisions 01.28.20


    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20

    • Biologics, Proteins, Vaccines
      Regenerative Medicine: Overcoming the supply chain challenges

      Regenerative Medicine: Overcoming the supply chain challenges

      Accomplishing the goal of widespread use of regenerative medicine doesn’t come without its challenges.
      Rich Quelch, Global Head of Marketing, Origin 11.20.19

    • Biologics, Proteins, Vaccines
      Challenges and Opportunities in Vaccines Drug Development

      Challenges and Opportunities in Vaccines Drug Development

      As the uptake in vaccines continues to fall, the general public needs to be better informed.
      Adrian Wildfire, Scientific Director, SGS Life Sciences 11.20.19

    Trending
    • Catalent Acquires Acorda’s INBRIJA Manufacturing Operations
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • Precision Medicine Group Acquires Project Farma
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    Breaking News
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    • Charles River Partners with JADE
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Eriocitrin Shown to Have Metabolic Benefits in Recent Study
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    Amyris Named a Top Social & Environmental Impact Company
    L'Oréal Bans Animal Hair in Brushes
    Ashland Launches Antaron ECo Gel
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login